N/A N=60 Smart Capsule for Automatic Adherence Monitoring
Medication Adherence
Primary: Medication Adherence — 88.1; 96.6; 94.4 percentage of doses taken (pill count)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=375 Observational Study On Compliance Of Statin Treatment Of Patients With High Blood Cholesterol Levels
Dyslipidemia
Primary: Percentage of Participants Who Were Compliant With Statin Treatment — 86.7 Percentage of participants
N/A N=257 Compliance With Treatment For Patients With Hyperlipidemia
Hyperlipidemia
Primary: Percentage of Participants With Positive Response on Increased Motivation Using a Self-test at Month 12 — 36.2 Percentage of participants
Phase 4 N=154 Self-management of Low Molecular Weight Heparin Therapy
Thromboembolism
Primary: Drug Use Problems — 1.25; 0.86; 1.20; 1.17 scores on a scale
N/A N=40 Assessing the Effectiveness and Safety of the ID-Cap System for Medication Monitoring and Adherence
Medication Adherence
Primary: Medication Adherence — 94.8; 82.8 percentage of doses taken
N/A N=294 Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)
Hepatitis C, Chronic · Hepatitis C
Primary: Number of Participants Who Are Triple-80 Compliant — 183 Participants
Phase 4 N=262 Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia
Dyspepsia · Compliance · Depression
Primary: Compliance of Flupentixol-Melitracen — 44; 28; 31 participants
N/A N=50 Effects of Use of a Connected Pillbox On Medication Adherence
Diabetes Mellitus · Hypertension · Hyperlipidemia
Primary: Percent of Participants With Adherence at Month 6 — 91; 40 percent persistent on therapy — p=<0.05
Phase 4 N=197 Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Chronic Hepatitis C · Genotype 1
Primary: Treatment Duration Compliance Rate — 85.4; 83.8 Percentage of compliance — p=0.4864
N/A N=72 Improving Medication Compliance and Smoking Cessation Treatment Outcomes for African American Smokers
Smokers
Primary: Percent Compliance With Chantix — 90.7; 85.8; 87.1; 91.7 Percentage of Participants
N/A N=67 Outcomes of Compliance With Brace Wear in Clubfoot
Clubfoot
Primary: Wear Rate Percentage (Number of Hours Per Day Brace Was Worn Out of the Recommended 24 Hours) — 91.7; NA; NA; 86.8 percentage of time worn
N/A N=3,828 Effectiveness and Patient Self-assessed Compliance of Blood Pressure Treatment With Tarka® Fixed Combination in Patients With Essential Hypertension
Essential Hypertension
Primary: Compliance With Tarka Treatment, All Participants and by Gender. — 2190; 1141; 1049; 1095 participants
N/A N=48 Auto Bilevel Adherence Following a Poor Initial Encounter With Continuous Positive Airway Pressure (CPAP)
Obstructive Sleep Apnea
Primary: Group Compliance of the Auto Bilevel Group Compared to the CPAP Group Measured by Average Nightly Use. — 284.7; 255.1 minutes/night — p=0.377
N/A N=153 Non-compliance on Treatment Among Diabetic Students at Sohag University
Diabetes Mellitus, Type 1
Primary: Distribution of Participants Responses as Regards DSMQ Glucose Management Domain — 13; 56; 39; 45 Participants
N/A N=2,430 Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)
Hepatitis C, Chronic · Hepatitis C
Primary: Number of Participants Achieving Viral Response at Any Evaluation Point (Stage 1) — 685 participants
N/A N=5,421 Medication Adherence Clinical Decision Support
Hyperlipidemia · Hypertension · Diabetes
Primary: Blood Pressure Medication Adherence — 396; 470 Participants — p=0.0103
N/A N=39 Efficacy of Glaucoma Drop Aids in Medication Compliance in the Patient Population at Boston Medical Center
Glaucoma
Primary: Number of Participants Assessed for Intraocular Pressure Change — 0; 4; 4; 8 Participants
N/A N=401 SATisfaction and Adherence to COPD Treatment
Pulmonary Disease, Chronic Obstructive
Primary: The Patients' Satisfaction With Chronic Obstructive Pulmonary Disease (COPD) Medical Treatments During a 12-month Observation Period — 64.2; 66.2; 67.1; 75.8 Unit on Scale
N/A N=200 Social Forces to Improve Statin Adherence (Study A)
Medication Adherence · High Blood Pressure · Diabetes
Primary: Statin Adherence — 86; 85; 86; 85 percentage of correct statin doses
N/A N=476 Behavioral Economic Strategies to Improve PRO Adherence
Cancer
Primary: PRO Adherence — 50.0; 56.9; 34.9 pct. assigned questionnaires completed
N/A N=165 Intervention to Improve Inhalative Adherence
Chronic Asthma · COPD
Primary: Time to Next Asthma or COPD Exacerbation up to 182 Days — 172; 161 days to first exacerbation
N/A N=201 Social Forces to Improve Statin Adherence (Study B)
Medication Adherence · High Blood Pressure · Diabetes
Primary: Statin Adherence — 79; 84; 80 percentage of correct statin doses
N/A N=62 Medication Adherence Patterns in Rheumatic Diseases: A Behavioral Trial
Rheumatic Diseases · Gout · Adherence, Medication
Primary: Rate of Medication Adherence — 0.76; 0.79; 0.83 percentage of doses taken — p=0.78
N/A N=124 Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA
Premature Infants
Primary: Number of Injections Per Patient Per Season — 3.8; 3.9; 4.0; 1.0 Injections administered
Phase 4 N=138 Adherence Study in COPD Patients
Chronic Obstructive Pulmonary Disease (COPD
Primary: Mean Number of Adherent Sets of Symbicort Puffs Per Day Over the 26-Week Study Period — 1.3; 1.6 Adherent sets of puffs / day — p=<0.001
N/A N=75 Patient-Centered Medication Adherence Intervention for Schizophrenia
Schizophrenia
Primary: Antipsychotic Medication Adherence — 63.9; 75.0 percentage of participants — p=0.03
N/A N=23 Medication Adherence With Polyglot Meducation
Hypertension · Diabetes · Hypercholesterolemia
Primary: Medication Possession Ratio at Baseline — 65.0 percentage of medication possession
N/A N=438 Interventions to Improve Specialty Medication Adherence
Adherence, Medication · Nonadherence, Medication
Primary: Median Proportion of Days Covered (PDC) at 8-months Post-enrollment — 0.94; 0.88 proportion of days covered (PDC) — p=0.001
N/A N=58 Impact on Instructional Video on Patients' Compliance With Preparation During CT Planning for Prostate Cancer
Latent Cancer (Prostate)
Primary: Number of Participants Whom Had Proper Preparation After Education Intervention — 22; 22; 7; 7 participants
N/A N=200 Does a Patient Education Video Augment Pelvic Floor Physical Therapy Compliance?
Patient Compliance · Pelvic Floor Disorders
Primary: Number of Participants With Completed PT Visits — 47; 50; 11; 21 Participants — p=0.17